ARDELYX INC. - COMMON STOCK
4.1300
02-May-25 16:45:00
15 minutes delayed
Stocks
-1.3400
-24.50%
Today's range
4.1000 - 4.5700
ISIN
N/A
Source
NASDAQ
-
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
31 Oct 2024 16:02:40 By Nasdaq GlobeNewswire
-
28 Oct 2024 16:05:00 By Nasdaq GlobeNewswire
-
24 Oct 2024 16:05:00 By Nasdaq GlobeNewswire
-
22 Oct 2024 16:05:00 By Nasdaq GlobeNewswire
-
21 Oct 2024 16:05:00 By Nasdaq GlobeNewswire
-
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
17 Oct 2024 08:00:00 By Nasdaq GlobeNewswire
-
09 Oct 2024 08:05:00 By Nasdaq GlobeNewswire
-
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire
-
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire
-
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
01 Aug 2024 16:01:02 By Nasdaq GlobeNewswire
-
31 Jul 2024 08:02:00 By Nasdaq GlobeNewswire
-
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
18 Jul 2024 08:00:00 By Nasdaq GlobeNewswire
-
17 Jul 2024 17:10:43 By Nasdaq GlobeNewswire
-
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
02 Jul 2024 07:00:00 By Nasdaq GlobeNewswire
-
28 Jun 2024 08:17:59 By Nasdaq GlobeNewswire
-
Ardelyx, Inc. Reports Employment Inducement Grants
30 May 2024 16:02:00 By Nasdaq GlobeNewswire
-
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
22 May 2024 08:02:00 By Nasdaq GlobeNewswire
-
21 May 2024 08:02:21 By Nasdaq GlobeNewswire
-
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
16 May 2024 08:01:41 By Nasdaq GlobeNewswire